Recent News

• 04.21.2025 - IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
• 03.24.2025 - IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
• 02.27.2025 - Imunon Fourth Quarter 2024 Financial Results
• 02.27.2025 - IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
• 02.26.2025 - IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Recent Filings

• 04.04.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.24.2025 - 8-K Current report
• 03.24.2025 - EX-99.1 EX-99.1
• 03.19.2025 - DRS Draft Registration Statement
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities